JP2022538868A5 - - Google Patents

Info

Publication number
JP2022538868A5
JP2022538868A5 JP2021577297A JP2021577297A JP2022538868A5 JP 2022538868 A5 JP2022538868 A5 JP 2022538868A5 JP 2021577297 A JP2021577297 A JP 2021577297A JP 2021577297 A JP2021577297 A JP 2021577297A JP 2022538868 A5 JP2022538868 A5 JP 2022538868A5
Authority
JP
Japan
Prior art keywords
approximately
item
micelle
cationic carrier
micelle according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021577297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538868A (ja
JP7665540B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/056093 external-priority patent/WO2020261227A1/en
Publication of JP2022538868A publication Critical patent/JP2022538868A/ja
Publication of JP2022538868A5 publication Critical patent/JP2022538868A5/ja
Priority to JP2025064597A priority Critical patent/JP2025106480A/ja
Application granted granted Critical
Publication of JP7665540B2 publication Critical patent/JP7665540B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021577297A 2019-06-26 2020-06-26 ミセルナノ粒子及びその使用 Active JP7665540B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064597A JP2025106480A (ja) 2019-06-26 2025-04-09 ミセルナノ粒子及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962867097P 2019-06-26 2019-06-26
US62/867,097 2019-06-26
US202063043693P 2020-06-24 2020-06-24
US63/043,693 2020-06-24
PCT/IB2020/056093 WO2020261227A1 (en) 2019-06-26 2020-06-26 Micellar nanoparticles and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064597A Division JP2025106480A (ja) 2019-06-26 2025-04-09 ミセルナノ粒子及びその使用

Publications (3)

Publication Number Publication Date
JP2022538868A JP2022538868A (ja) 2022-09-06
JP2022538868A5 true JP2022538868A5 (https=) 2023-06-29
JP7665540B2 JP7665540B2 (ja) 2025-04-21

Family

ID=74060198

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577297A Active JP7665540B2 (ja) 2019-06-26 2020-06-26 ミセルナノ粒子及びその使用
JP2025064597A Pending JP2025106480A (ja) 2019-06-26 2025-04-09 ミセルナノ粒子及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064597A Pending JP2025106480A (ja) 2019-06-26 2025-04-09 ミセルナノ粒子及びその使用

Country Status (14)

Country Link
US (3) US20220257790A1 (https=)
EP (2) EP3990028B1 (https=)
JP (2) JP7665540B2 (https=)
KR (2) KR20240039234A (https=)
CN (1) CN114514038B (https=)
AU (1) AU2020303447A1 (https=)
BR (1) BR112021026365A2 (https=)
CA (1) CA3144333A1 (https=)
CO (1) CO2022000316A2 (https=)
DK (1) DK3990028T3 (https=)
IL (1) IL289258A (https=)
MX (1) MX2022000045A (https=)
PE (1) PE20220902A1 (https=)
WO (1) WO2020261227A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10844380B1 (en) 2019-06-17 2020-11-24 Biorchestra Co., Ltd. Uses for prevention or treatment of brain diseases using microrna
CN117024749A (zh) 2019-06-28 2023-11-10 国立大学法人东京大学 蛋白质内包高分子胶束
US20230099372A1 (en) * 2020-02-07 2023-03-30 Biorchestra Co., Ltd. Use of mirna-485 inhibitors for treating tauopathy
US11761874B2 (en) * 2020-05-15 2023-09-19 Saudi Arabian Oil Company CMC-based method for surfactant concentration determination
WO2022075470A1 (ja) * 2020-10-09 2022-04-14 国立大学法人 東京大学 ニコチンアミド内包ミセル、及びニコチンアミド内包ミセルを含む妊娠高血圧症候群治療用組成物
CN116963722A (zh) * 2020-12-30 2023-10-27 生物欧赛加有限责任公司 胶束纳米粒子及其用途
WO2022144811A1 (en) * 2020-12-30 2022-07-07 Biorchestra Co., Ltd. Micellar nanoparticles and uses thereof
US20250313835A1 (en) * 2022-07-07 2025-10-09 Biorchestra Co., Ltd. Micellar nanoparticles and uses thereof
CN115721608A (zh) * 2022-11-29 2023-03-03 陕西科技大学 一种靶向温度敏感性聚合物胶束、制备方法及应用
WO2024228118A1 (en) * 2023-05-01 2024-11-07 Biorchestra Co., Ltd. Mirna-485 inhibitors
WO2024228119A1 (en) * 2023-05-01 2024-11-07 Biorchestra Co., Ltd. Mirna-485 inhibitors
WO2025149946A1 (en) * 2024-01-10 2025-07-17 Biorchestra Co., Ltd. Micellar nanoparticles and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
EP1553924B1 (en) 2002-06-26 2010-12-08 MediGene AG Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US8969314B2 (en) 2003-07-31 2015-03-03 Regulus Therapeutics, Inc. Methods for use in modulating miR-122a
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
WO2006093526A2 (en) 2004-07-21 2006-09-08 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
AU2005330637B2 (en) 2004-08-04 2012-09-20 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
AU2006279906B2 (en) 2005-08-10 2012-05-10 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
EP1931780B1 (en) 2005-08-29 2016-01-06 Regulus Therapeutics Inc. Antisense compounds having enhanced anti-microrna activity
AU2007211082B2 (en) 2006-01-27 2012-09-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
EP2007888A2 (en) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2090665A2 (en) 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
WO2008074328A2 (en) 2006-12-21 2008-06-26 Exiqon A/S Microrna target site blocking oligos and uses thereof
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
US20090156459A1 (en) * 2007-11-16 2009-06-18 Pharmain Corporation Cationic-Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2010005581A1 (en) * 2008-07-11 2010-01-14 Kareus Therapeutics, Llc Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad)
JP5622254B2 (ja) * 2009-03-31 2014-11-12 国立大学法人東京大学 二本鎖リボ核酸ポリイオンコンプレックス
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
CA2769162C (en) * 2009-07-31 2017-12-05 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
JP5820378B2 (ja) * 2009-09-09 2015-11-24 ファーマイン コーポレーションＰｈａｒｍａｉｎ Ｃｏｒｐｏｒａｔｉｏｎ 治療剤の送達のための陰イオンコア組成物およびその製造ならびに使用方法
US20120005765A1 (en) * 2010-07-01 2012-01-05 Saint Louis University Animal model for parkinson's disease
EP2619189B1 (en) 2010-09-24 2020-04-15 Zoetis Services LLC Isoxazoline oximes as antiparasitic agents
US20140371292A1 (en) * 2011-08-10 2014-12-18 Ludwig-Maximilians-Universitat Munchen Method for the controlled intracellular delivery of nucleic acids
CN105792850A (zh) * 2013-12-05 2016-07-20 念·吴 聚合物-碳水化合物的缀合物的药物转递技术
JP2017512757A (ja) * 2014-02-24 2017-05-25 ウリゲン ファーマシューティカルズ、インコーポレイテッド 経口投与するためのペントサンポリ硫酸塩の組成物および使用の方法
WO2016086177A2 (en) * 2014-11-25 2016-06-02 Drexel University Compositions and methods for hiv quasi-species excision from hiv-1-infected patients
DK3378482T5 (da) * 2015-11-19 2024-09-30 Univ Nagoya City Public Univ Corp Formulering til administration af antitumorlægemiddel
WO2017212007A1 (en) 2016-06-09 2017-12-14 Curevac Ag Cationic carriers for nucleic acid delivery
WO2018053316A1 (en) 2016-09-15 2018-03-22 The Regents Of The University Of California Improved hybrid telodendrimers
RU2016146594A (ru) * 2016-11-28 2018-05-28 Общество С Ограниченной Ответственностью "Биофарм-Меморейн" Средство для лечения деменции различной этиологии
AU2017378427A1 (en) 2016-12-14 2019-06-20 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery
WO2018139759A1 (ko) * 2017-01-26 2018-08-02 주식회사 바이오오케스트라 마이크로 rna를 이용한 알츠하이머병 진단방법
WO2018144022A1 (en) 2017-02-03 2018-08-09 Farokhzad Omid C Particles as delivery systems
CN110156971A (zh) 2018-02-13 2019-08-23 上海时莱生物技术有限公司 一种两亲性嵌段共聚物及其制备方法和纳米胶束载药系统
US11857634B2 (en) 2018-04-20 2024-01-02 University of Pittsburgh—of the Commonwealth System of Higher Education Cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids
CN111632153B (zh) 2020-06-23 2023-02-24 宁夏医科大学 一种化学基因药物共载的靶向纳米递药系统及其制备方法
WO2022144811A1 (en) 2020-12-30 2022-07-07 Biorchestra Co., Ltd. Micellar nanoparticles and uses thereof
JP2024503303A (ja) 2020-12-30 2024-01-25 バイオーケストラ カンパニー， リミテッド ミセルナノ粒子及びその使用

Similar Documents

Publication Publication Date Title
JP2022538868A5 (https=)
US12180477B2 (en) Dynamic pharmacokinetic-modifying anchors
EP3378482B1 (en) Antitumor drug delivery formulation
EP2796150B1 (en) Novel oligonucleotide conjugates and use thereof
JP2025106480A5 (https=)
EP2892505B1 (en) Lipid assemblies comprising anionic lysolipids and use thereof
US20230061751A1 (en) Universal dynamic pharmacokinetic-modifying anchors
US20220267775A1 (en) CANCER TREATMENT USING TARGETED siRNA PHARMACEUTICAL FORMULATIONS TO DOWNREGULATE EXPRESSION OF PRDM14 PROTEIN
Sarisozen et al. Lipid-based siRNA delivery systems: challenges, promises and solutions along the long journey
Xu et al. Efficient siRNA delivery using PEG-conjugated PAMAM dendrimers targeting vascular endothelial growth factor in a CoCl2-induced neovascularization model in retinal endothelial cells
JP2024503302A5 (https=)
tinkaya et al. MicroRNAs and long non-coding RNAs as novel targets in Anti-cancer drug development
JP2017502959A (ja) 生体内及び体外で核酸類薬物を送達するための新規な糖アルコール類組成物
IL316806A (en) Compositions and methods for treating monogenic neurodevelopmental disorder
JP2023532536A5 (https=)
JP2024503303A5 (https=)
JP2023513188A5 (https=)
JP2023513190A5 (https=)
WO2022040168A2 (en) Anti-seed pnas and microrna inhibition
KR20240072931A (ko) 히스티딘을 포함하는 지질 나노입자 및 그 제조방법
WO2023215878A2 (en) Calcium salted spherical nucleic acids
CN118695875A (zh) 在用于治疗和/或预防疾病的方法中使用的制剂
JP2023513189A5 (https=)
CN111228505B (zh) 一种蒽醌类药物和核酸复合物纳米递送体系及其制备方法与应用
WO2023086935A2 (en) Aptamer-based small ribonucleic acid delivery platform and uses thereof